The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Viread     [[(2R)-1-(6-aminopurin-9- yl)propan-2...

Synonyms: Tenofovir DF, CHEMBL1486, Viread (TN), S1400_Selleck, cc-162, ...
This record was replaced with 5481350.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PMPA prodrug


Psychiatry related information on PMPA prodrug

  • OBJECTIVE: To evaluate the safety and efficacy of once daily doses of tenofovir DF (TDF) administered in combination with other antiretroviral therapy (ART) in treatment-experienced HIV-1-infected patients with incomplete virological suppression [5].

High impact information on PMPA prodrug


Chemical compound and disease context of PMPA prodrug


Biological context of PMPA prodrug


Anatomical context of PMPA prodrug


Associations of PMPA prodrug with other chemical compounds


Gene context of PMPA prodrug


Analytical, diagnostic and therapeutic context of PMPA prodrug


  1. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda, K., Vela, J.E., Myrick, F., Ray, A.S., Miller, M.D. Antivir. Ther. (Lond.) (2006) [Pubmed]
  2. An introduction to nucleoside and nucleotide analogues. Squires, K.E. Antivir. Ther. (Lond.) (2001) [Pubmed]
  3. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Benhamou, Y., Fleury, H., Trimoulet, P., Pellegrin, I., Urbinelli, R., Katlama, C., Rozenbaum, W., Le Teuff, G., Trylesinski, A., Piketty, C. Hepatology (2006) [Pubmed]
  4. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Wong, S.N., Lok, A.S. Hepatology (2006) [Pubmed]
  5. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. Schooley, R.T., Ruane, P., Myers, R.A., Beall, G., Lampiris, H., Berger, D., Chen, S.S., Miller, M.D., Isaacson, E., Cheng, A.K. AIDS (2002) [Pubmed]
  6. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Peters, M.G., Andersen, J., Lynch, P., Liu, T., Alston-Smith, B., Brosgart, C.L., Jacobson, J.M., Johnson, V.A., Pollard, R.B., Rooney, J.F., Sherman, K.E., Swindells, S., Polsky, B. Hepatology (2006) [Pubmed]
  7. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. Margot, N.A., Isaacson, E., McGowan, I., Cheng, A.K., Schooley, R.T., Miller, M.D. AIDS (2002) [Pubmed]
  8. Treating chronic hepatitis B: today and tomorrow. Borgia, G., Gentile, I. Current medicinal chemistry. (2006) [Pubmed]
  9. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Delaney, W.E., Ray, A.S., Yang, H., Qi, X., Xiong, S., Zhu, Y., Miller, M.D. Antimicrob. Agents Chemother. (2006) [Pubmed]
  10. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Kearney, B.P., Yale, K., Shah, J., Zhong, L., Flaherty, J.F. Clinical pharmacokinetics. (2006) [Pubmed]
  11. Antiviral Activities of Novel 5-Phosphono-Pent-2-en-1-yl Nucleosides and Their Alkoxyalkyl Phosphonoesters. Choo, H., Beadle, J.R., Kern, E.R., Prichard, M.N., Keith, K.A., Hartline, C.B., Trahan, J., Aldern, K.A., Korba, B.E., Hostetler, K.Y. Antimicrob. Agents Chemother. (2007) [Pubmed]
  12. Tenofovir disoproxil fumarate. Chapman, T., McGavin, J., Noble, S. Drugs (2003) [Pubmed]
  13. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Guo, Y., Fung, H.B. Pharmacotherapy (2004) [Pubmed]
  14. Treatment of chronic hepatitis B in HIV co-infected patients. Guan, R. Med. J. Malaysia (2005) [Pubmed]
  15. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Hazra, R., Balis, F.M., Tullio, A.N., DeCarlo, E., Worrell, C.J., Steinberg, S.M., Flaherty, J.F., Yale, K., Poblenz, M., Kearney, B.P., Zhong, L., Coakley, D.F., Blanche, S., Bresson, J.L., Zuckerman, J.A., Zeichner, S.L. Antimicrob. Agents Chemother. (2004) [Pubmed]
  16. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Gallant, J.E., Rodriguez, A.E., Weinberg, W.G., Young, B., Berger, D.S., Lim, M.L., Liao, Q., Ross, L., Johnson, J., Shaefer, M.S. J. Infect. Dis. (2005) [Pubmed]
  17. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Kearney, B.P., Flaherty, J.F., Shah, J. Clinical pharmacokinetics. (2004) [Pubmed]
  18. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Frampton, J.E., Croom, K.F. Drugs (2006) [Pubmed]
  19. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. van Gelder, J., Deferme, S., Naesens, L., De Clercq, E., van den Mooter, G., Kinget, R., Augustijns, P. Drug Metab. Dispos. (2002) [Pubmed]
  20. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Biesecker, G., Karimi, S., Desjardins, J., Meyer, D., Abbott, B., Bendele, R., Richardson, F. Antiviral Res. (2003) [Pubmed]
  21. Gateways to clinical trials. Bayes, M., Rabasseda, X., Prous, J.R. Methods and findings in experimental and clinical pharmacology. (2004) [Pubmed]
  22. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Neff, G.W., O'brien, C.B., Nery, J., Shire, N., Montalbano, M., Ruiz, P., Nery, C., Safdar, K., De Medina, M., Tzakis, A.G., Schiff, E.R., Madariaga, J. Liver Transpl. (2004) [Pubmed]
  23. New nucleoside/nucleotide backbone options: a review of recent studies. Ruane, P.J., DeJesus, E. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  24. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. Jones, R., Stebbing, J., Nelson, M., Moyle, G., Bower, M., Mandalia, S., Gazzard, B. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  25. Resistance issues with new nucleoside/nucleotide backbone options. Wainberg, M.A., Turner, D. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  26. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Mallants, R., Van Oosterwyck, K., Van Vaeck, L., Mols, R., De Clercq, E., Augustijns, P. Xenobiotica (2005) [Pubmed]
  27. Gateways to clinical trials. Bayés, M., Rabasseda, X., Prous, J.R. Methods and findings in experimental and clinical pharmacology. (2005) [Pubmed]
  28. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Masquelier, B., Tamalet, C., Montès, B., Descamps, D., Peytavin, G., Bocket, L., Wirden, M., Izopet, J., Schneider, V., Ferré, V., Ruffault, A., Palmer, P., Trylesinski, A., Miller, M., Brun-Vézinet, F., Costagliola, D. Antivir. Ther. (Lond.) (2004) [Pubmed]
  29. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. Louie, M., Hogan, C., Hurley, A., Simon, V., Chung, C., Padte, N., Lamy, P., Flaherty, J., Coakley, D., Di Mascio, M., Perelson, A.S., Markowitz, M. AIDS (2003) [Pubmed]
  30. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. Miller, M.D., Margot, N., McColl, D., Cheng, A.K. AIDS (2007) [Pubmed]
  31. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Menne, S., Cote, P.J., Korba, B.E., Butler, S.D., George, A.L., Tochkov, I.A., Delaney, W.E., Xiong, S., Gerin, J.L., Tennant, B.C. Antimicrob. Agents Chemother. (2005) [Pubmed]
WikiGenes - Universities